#USA #New York #Inc. #Securities Fraud #Pomerantz Law Firm #Merck & Co.

Investor Alert: Class Action Lawsuit Filed Against Merck & Co.

The Pomerantz Law Firm has stepped forward to remind investors who have faced losses on their investments in Merck & Co., Inc. about an upcoming class action lawsuit. Investors are strongly encouraged to take action promptly, as crucial deadlines are approaching.

This class action lawsuit revolves around whether Merck, along with some of its executives and directors, has been involved in securities fraud or other illegal business activities. Investors who acquired Merck securities during the specified class period should reach out to Pomerantz LLP to potentially become lead plaintiffs in this case. Contacts are available through their representative, Danielle Peyton, either via email or phone.

Background on Merck’s Recent Performance

On July 30, 2024, Merck released its financial results for Q2 2024, drawing attention to a sharp decline in demand for its HPV vaccination, Gardasil, in China. This news led to significant inventory challenges, prompting the company to forecast shipments falling short of contractual commitments for the year. As a direct response to this revelation, Merck's stock experienced a notable drop, plummeting by over $12.53, marking almost a 10% drop in its share price shortly after the announcement.

Further compounding this situation, on February 4, 2025, Merck disclosed that it would not be meeting its previously announced forecast of $11 billion in Gardasil sales for 2030. The company confirmed the cessation of shipments to China through at least midyear, aiming to rapidly reduce excess inventory levels. This announcement led to another stock price decline, with shares falling by over $9.05 as investors reacted to the negative trajectory of the company's sales expectations.

Such developments have raised significant alarm among investors, many of whom are now grappling with substantial financial losses. With the lawsuit now filed, individuals affected are encouraged to consider their legal options before the looming deadline of April 14, 2025, for submitting requests to be appointed as lead plaintiffs.

About Pomerantz Law Firm

Pomerantz LLP has established itself as a leading firm in the realm of corporate, securities, and antitrust class action litigation. The firm, founded by legal pioneer Abraham L. Pomerantz, has over 85 years of experience in championing the rights of victims arising from securities fraud and corporate misconduct. They take pride in their history of recovering significant damages on behalf of class members, and they continue to operate with a commitment to providing justice for affected investors.

For any investors who purchased shares of Merck during the specified periods, it is critical to act swiftly to protect your interests. A full copy of the filed complaint is available on the firm’s official website for those who wish to gain further insight into the legal action being pursued against Merck. The firm’s representatives are also on hand to answer any questions and guide potential plaintiffs through the next steps in the legal process.

In light of the growing scrutiny surrounding Merck & Co.'s business practices, staying informed and acting proactively will be essential for investors seeking to safeguard their financial interests in this unfolding situation.

• ---